Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1,066 MXN
Change Today 0.00 / 0.00%
Volume 0.0
AZNN On Other Exchanges
Symbol
Exchange
New York
Xetra
London
Stockholm
OTC US
Mexico
Berlin
As of 4:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

astrazeneca plc-spons adr (AZNN) Snapshot

Open
$1,066
Previous Close
$1,066
Day High
$1,066
Day Low
$1,066
52 Week High
03/27/15 - $1,066
52 Week Low
04/8/14 - $827.00
Market Cap
1.3T
Average Volume 10 Days
52.2
EPS TTM
--
Shares Outstanding
1.3B
EX-Date
02/18/15
P/E TM
--
Dividend
$3.72
Dividend Yield
3.77%
Current Stock Chart for ASTRAZENECA PLC-SPONS ADR (AZNN)

astrazeneca plc-spons adr (AZNN) Details

AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. Its principal products include Crestor for the treatment of dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL to control hypertension, and heart failure and angina; Onglyza for diabetes mellitus; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; and Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders. The company's principal products also comprise Pulmicort Turbuhaler/Pulmicort Flexhaler for treating asthma; Symbicort for maintenance treatment of asthma and chronic obstructive pulmonary disease; Nexium for treatment of acid-related diseases; Seroquel XR for the treatment of schizophrenia, bipolar disorder, major depressive disorder, and generalised anxiety disorder; and Synagis for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus in paediatric patients. As of December 31, 2014, it had 133 pipeline projects. The company markets its products through distributors and local representative offices. In addition, it engages in the insurance and reinsurance underwriting business. The company has collaboration agreements with Immunocore Limited, Kyowa Hakko Kirin Co., Ltd., Advaxis Inc., and Pharmacyclics Inc. and Janssen Research & Development, LLC. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in London, the United Kingdom.

57,500 Employees
Last Reported Date: 03/10/15
Founded in 1992

astrazeneca plc-spons adr (AZNN) Top Compensated Officers

Chief Executive Officer, Executive Director a...
Total Annual Compensation: 3.1M GBP
Chief Financial Officer and Executive Directo...
Total Annual Compensation: 1.7M GBP
Compensation as of Fiscal Year 2014.

astrazeneca plc-spons adr (AZNN) Key Developments

AstraZeneca's BRILINTA 90 Receives US FDA Approval for New Administration Option

AstraZeneca announced that the US Food and Drug Administration (FDA) has approved a new administration option for acute coronary syndrome (ACS) patients who are unable to swallow BRILINTA 90 mg tablets whole. Unlike other P2Y12 inhibitors, BRILINTA has FDA approval to be crushed and administered in water by swallowing or via nasogastric tube. BRILINTA is a direct-acting P2Y12 receptor antagonist in a chemical class called cyclopentyltriazolopyrimidines (CPTPs). BRILINTA works by inhibiting platelet activation and has been shown to reduce the rate of thrombotic cardiovascular (CV) events, such as a heart attack or CV death, in patients with acute coronary syndrome (ACS). BRILINTA is available in 90-mg tablets to be administered with a single 180-mg oral loading dose (two 90-mg tablets) followed by a twice daily, 90-mg maintenance dose. Following an initial loading dose of aspirin, BRILINTA should be used with a maintenance dose of 75 mg - 100 mg aspirin once daily, 81-mg aspirin dose in the US.

Shire, AstraZeneca And Roche Show Interest In BioMarin

After several media outlets reported that Shire plc (LSE:SHP), AstraZeneca PLC (LSE:AZN) and Roche Holding AG (SWX:ROG) are considering buying BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), SunTrust says that it would be logical for several drug companies looking to build or expand their orphan disease franchises to buy BioMarin.

AstraZeneca and Daiichi Sankyo, Inc. Partner to Commercialize OIC Drug in US

AstraZeneca has announced a co-commercialization agreement with Daiichi Sankyo Inc. for MOVANTIK, a once-daily oral peripherally-acting mu-opioid receptor antagonist, or PAMORA, for the treatment of opioid-induced constipation, or OIC, in adults with chronic non-cancer pain, in the US. MOVANTIK was approved by the FDA in September 2014. It was descheduled by the US Drug Enforcement Administration in January 2015 and is no longer labelled as a controlled substance. The launch of MOVANTIK in the US is planned for early April 2015. Under the terms of the agreement, Daiichi Sankyo Inc. will pay a $200 million up-front fee and subsequent sales-related payments of up to $625 million. AstraZeneca will be responsible for manufacturing, will book all sales and will make sales-related commission payments to Daiichi Sankyo Inc. Both companies will be jointly responsible for commercial activities.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AZNN:MM $1,065.50 MXN 0.00

AZNN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $58.54 USD +0.30
Bristol-Myers Squibb Co $64.50 USD -1.26
Eli Lilly & Co $72.65 USD -1.22
Novo Nordisk A/S kr372.00 DKK -4.80
Valeant Pharmaceuticals International Inc C$250.21 CAD -6.46
View Industry Companies
 

Industry Analysis

AZNN

Industry Average

Valuation AZNN Industry Range
Price/Earnings 71.5x
Price/Sales 3.4x
Price/Book 4.5x
Price/Cash Flow 71.4x
TEV/Sales 3.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTRAZENECA PLC-SPONS ADR, please visit www.astrazeneca.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.